OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2013
(2)
2023
(1)
2017
(1)
2016
(1)
2014
(1)
2012
(1)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
Not available
S-EPMC3041205
|
biostudies-literature
Cite
Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
®
T1).
Not available
S-EPMC5248618
|
biostudies-literature
Cite
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
Not available
S-EPMC3832772
|
biostudies-literature
Cite
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Not available
S-EPMC5070831
|
biostudies-literature
Cite
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Not available
S-EPMC3747917
|
biostudies-literature
Cite
Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimester.
Not available
S-EPMC3877859
|
biostudies-literature
Cite
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Not available
S-EPMC3476910
|
biostudies-literature
Cite
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Not available
S-EPMC10469096
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets